Oxford Biomedica, AstraZeneca enter new deal for Covid-19 vaccine
According to the new deal, AstraZeneca will have access to Covid-19 vaccine manufacturing at Oxford Biomedica’s Oxbox facility.

According to the new deal, AstraZeneca will have access to Covid-19 vaccine manufacturing at Oxford Biomedica’s Oxbox facility.
At the closing of the deal, Blueprint will get a total of $575m in cash.
Under the deal, Twist will receive upfront, milestone and royalty payments as well as annual maintenance fees.
The filing is based on non-clinical and clinical data for Paxlovid and also comprised data from the Phase II/III EPIC-HR…
Following the acquisition, Amgen Turkey will maintain its operations and serve its patients in the region.
Gemcovac became the first saRNA vaccine to obtain approval for use in humans in India.
This deal might comprise Omicron-adapted Covid-19 vaccines contingent on obtaining the US FDA authorisation.
The filing is based on data from six clinical trials in subjects of the age 18 years and above.
Thank you for subscribing to Pharmaceutical Technology